Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

TRYP Therapeutics Inc. (C:TRYP)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for TRYP within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jan 19, 2021 07:00 ET
Tryp Therapeutics Invited to Present at "Investing in Psychedelics" Conference
La Jolla, California--(Newsfile Corp. - January 19, 2021) -  Tryp Therapeutics (CSE: TRYP), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, has been invited to present at the upcoming Investing in Psychedelics Conference hosted by The CSE (Canadian Securities Exchange).
Read full article
Jan 14, 2021 07:00 ET
Tryp Therapeutics Strengthens Board of Directors with Appointment of Gregory M. McKee
La Jolla, California--(Newsfile Corp. - January 14, 2021) - Tryp Therapeutics Inc. (CSE: TRYP) ("Tryp" or the "Company"), a pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, is pleased to announce the appointment of Gregory M. McKee to the Company's board of directors.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
N/A
--
--
Price to Sales - TTM
--
16.87
14.55
Price to Book - most recent quarter
--
6.29
4.36
Price to Cash Flow per share - TTM
--
5.75
17.75
Price to Free Cash Flow per share - TTM
--
37.40
28.48
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jan 15, 202185,750-129,747
Dec 31, 2020215,4970
Dec 31, 196900
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

Tryp Therapeutics Inc. is a Canada-based clinical stage pharmaceutical company. The Company is focused on developing compounds for the treatment of rare or orphan diseases and other diseases with unmet medical needs. Its lead development program, psilocybinfor-neuropsychiatry (PFN) program, is designed to treat neuropsychiatric disorders through the dosing of formulations of synthetic psilocybin. The indication for its PFN program is fibromyalgia. The Company is also evaluating additional indications for its PFN program, including hyperphagia in Prader Willi syndrome (PWS) and other neuropsychiatric-based chronic pain conditions and eating disorders. The Company is also engaged in developing a formulation of razoxane for the treatment of soft tissue sarcomas.

See business summary

 

Twitter

Search (past week) for $TRYP.CA